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Background.WeaimedtoassesscardiacconductionsafetyofcoadministrationoftheCYP3A4inhibitorlopinavir/ritonavir(LPV/r)
and the CYP3A4 substrate artemether-lumefantrine (AL) in HIV-positive Ugandans. Methods.O p e n - l a b e ls a f e t ys t u d yo fH I V -
positive adults administered single-dose AL (80/400mg) alone or with LPV/r (400/100mg). Cardiac function was monitored
using continuous electrocardiograph (ECG). Results. Thirty-two patients were enrolled; 16 taking LPV/r -based ART and 16 ART
na¨ ıve. All took single dose AL. No serious adverse events were observed. ECG parameters in milliseconds remained within normal
limits. QTc measurements did not change signiﬁcantly over 72 hours although were higher in LPV/r arm at 24 (424 versus 406;
P = .02) and 72 hours (424 versus 408; P = .004) after AL intake. Conclusion. Coadministration of single dose of AL with LPV/r
was safe; however, safety of six-dose AL regimen with LPV/r should be investigated.
1.Introduction
Malaria and HIV infection are leading causes of morbidity
and mortality and remain major health problems in endemic
regions. Malaria causes about 300–500 million clinical cases
annually, 90% of which occur in sub-Saharan Africa [1].
The Joint United Nations Program on HIV/AIDS(UNAIDS)
estimated that 29.4 Million Africans are infected with HIV
(UNAIDS, December 2002). Together malaria and HIV
account for over four million deaths per year.
Studies have demonstrated increased risk for malaria in
HV infected patients especially those with lower CD4 cell
counts [2–4]. More evidence suggests transient increase in
HIV viral load in patients with acute malaria episodes [5]. A
major challenge to the treatment of malaria in HIV-infected
individuals is the potential for pharmacokinetic (PK) drug
interactions with concerns regarding safety and eﬃcacy [6].
Due to the widespread resistance to older antimalarial
drugs, the World Health Organization now recommends
artemisinin combination therapy (ACT) for malaria treat-
ment [7]. Artemether-lumefantrine (AL) is an oral ﬁxed-
dose combination tablet of artemether (a derivative of
artemisinin) and lumefantrine (a racemic mixture of a
synthetic ﬂuorine derivative). The drug combination is
highly eﬃcacious against sensitive and multidrug resistant
Plasmodium falciparum; with the advantage of rapid clear-
ance ofparasites by artemether and the slower elimination of
residual parasites by lumefantrine [7–9].2 Chemotherapy Research and Practice
Recommendations for antiretroviral therapy (ART)
include two nucleoside reverse transcriptase inhibitors
(NRTIs) plus a nonnucleoside reverse transcriptase inhibitor
( N N R T I )o rap r o t e a s ei n h i b i t o r( P I ) .L o p i n a v i r / r i t o n a v i r
(LPV/r) is an oral ﬁxed-dose combination tablet of LPV
(a PI) with low dose ritonavir, a pharmacoenhancer
that signiﬁcantly increases LPV plasma concentrations by
cytochrome P450 3A4 (CYP3A4) inhibition.
Concerns over safety monitoring of LPV/r have become
more crucialfollowing the recentFDAalert oncardiotoxicity
of LPV/r. Safety information on LPV/r includes warnings
and precautions regarding QT/QTC interval and PR interval
prolongation. According to the revised safety label, LPV/r
prolongs the PR interval, and cases of second- or third-
degree atrioventricular block have been reported in some
patients. Indeed LPV/r should be used with caution in
patients who may be at increased risk of developing cardiac
conduction abnormalities, such as those with underlying
structural heart disease, preexisting conduction system
abnormalities, ischemic heart disease, or cardiomyopathies.
The eﬀect on the PR interval of coadministration of LPV/r
with other drugs that prolong the PR interval has not yet
been determined and should be undertaken with caution.
Clinical monitoring is recommended especially during coad-
ministration with drugs metabolized by CYP3A [10].
Data from previous studies indicate that artemether and
lumefantrine are predominantly metabolized by CYP3A4 [6,
11,12].Knowledgeoftheirmetabolismsuggestspotentialfor
PK drug-drug interactions [6] .L P V / ri sap o t e n ti n h i b i t o ro f
CYP3A4, therefore, inhibition of CYP3A4 may raise plasma
concentrations of artemether and lumefantrine but decrease
plasma concentrations of dihydroartemisinin (DHA) the
metabolite of artemether. A study that investigated the
pharmacokinetics of AL when administered with LPV/r
in HIV-uninfected healthy volunteers demonstrated 2 to
3-fold increases in lumefantrine AUC and trends towards
decreases in artemether Cmax and AUC. Formal safety
analysis of coadministration was not performed in this study
[13]. Increased plasma concentrations of artemether and
lumefantrine may enhance toxicity. Lumefantrine has some
structural similarity to halofantrine which is cardiotoxic
mainly in form of QTc prolongation. Therefore, vigilant
evaluation of the cardiac safety of lumefantrine, especially
when coadministered with a potent CYP3A4 inhibitor, is
warranted [14–17]. We aimed to assess the cardiac safety of
coadministration of a single dose of AL (80/480mg) with
LPV/r based ART in HIV-positive Ugandan patients.
2.Materialsand Methods
2.1. Ethical Considerations. The study was approved by
the Scientiﬁc Review Committee of the Infectious Diseases
Institute (IDI) of Makerere University, the Uganda National
HIV/AIDS Research Committee (ARC 056) and was regis-
tered with Uganda National Council of Science and Tech-
nology (HS 197) and ClinicalTrials.gov (NCT 00619944).All
participants gave written informed consent to participate,
and all study procedures were conducted according to Good
Clinical Practice (GCP).
2.2. Study Site. The study was conducted between January
2008 and June 2009 at the IDI and the Uganda Heart
Institute (UHI) of Mulago National Referral Hospital in
Kampala, Uganda. The IDI is a regional centre of excellence
for HIV/AIDS treatment, prevention, training and research.
To date, over 20,000 HIV-infected patients are registered at
the IDI with over 8,000 taking ART. About 10% these are on
LPV/r-based second line ART.
2.3. Study Design and Population. This was a two-arm study
toassess thesafety ofcoadministration ofALin HIV-positive
patients taking LPV/r-based ART and ART na¨ ıve patients.
Patients were eligible to participate if they were older than
18 years of age, provided written informed consent, had no
evidenceofsystemic illness andrequirednomedicationsthat
had known potential for drug interactions with study drugs.
Patients with abnormal ECG tracing, abnormal clinical test
results, positive blood smear for malaria, pregnant mothers
and those who reported use of herbal medication were
excluded from the study.
2.4. Study Procedures. Patients were screened and enrolled
from the cohort of patients attending the IDI. The LPV/r
arm consisted of patients stable on LPV/r 400/100mg-based
ART for at least one month and the ART na¨ ıve arm consisted
of patients who had not started ART and were not yet
eligible for ART according to national guidelines. Patients in
both arms took cotrimoxazole daily for prophylaxis against
opportunistic infections. Participants had detailed study
explanation at enrolment. Adherence to study drugs was
assessed using self-report and pill count by the study phar-
macist. We collected information on adverse drug eventsand
serious adverse drug events, and a questionnaire on quality
of life was administered on each study day. On the evening
prior to the study day, participants were reminded of their
study day appointment, were given detailed instructions to
take their medication and food at 8.00 pm, and told to
arrive at the hospital by 7.00 am in a fasting state. On
the study day, patients were admitted at the UHI and a
12-lead ECG monitor was attached for continuous cardiac
function monitoring. The intake of a standardized breakfast
and morning doses of drugs was directly observed by study
staﬀ. All patients took a single dose of AL of 80/480mg
with 150mL of water. Patients in the LPV/r arm took LPV/r
(400/100mg) with their AL dose. ECG monitoring was
performedcontinuouslyfortheﬁrst12hoursafterALintake.
Patients were then discharged and returned for the following
three mornings (T = 24, 48, and 72 hours) for a single ECG
tracing.
2.5. Safety Assessment. Medical history, physical examina-
tion, vital signs, routine clinical laboratory tests, ECGs and
urine screens for pregnancy were performed at screening.
On the study day, medical history, physical examination,
vital signs, and a blood smear for malaria parasites were
performed. Adverse events were recorded continuously
throughout the trial, and the onset, duration, severity, and
relationship to the trial drugs if any were noted. StandardChemotherapy Research and Practice 3
Table 1:showsacomparisonofthebaselinecharacteristics ofstudy
patients.
Variable LPV/r arm ART na¨ ıve arm P value
median (IQR) median (IQR)
Age (yrs) 38 (33–41) 34 (28–39) .2
Weight (kgs) 65 (54–73) 64 (56–71) .9
Height (cms) 163(158–172) 163 (153–169) .1
BMI 21 (19–24) 25 (22–31) .06
Viral load (c/mL) <400 26756 (5548–181186) <.01
Hb (g/dL) 14 (14–15.4) 12.2 (12–14) .003
Table 2: shows the mean electrocardiograph (ECG) parameters in
milliseconds after AL dosing.
Variable LPV/r arm ART na¨ ıve arm P value
mean (SD) mean (SD)
Heart rate 69 (8.1) 71 (5.9) .5
PR 154 (18.4) 169 (15.9) .02
QRS 87.4 (6.6) 82.8 (6.6) .06
QTc 421 (20.0) 404 (20.7) .03
12-lead ECGs were recorded at screening, immediately prior
to dosing (T = 0 hour), and continuously for 12 hours
after dose of AL, then daily for three days. QTc-intervals
were calculated using the Bazett formula (QTc = QT/÷
√
RR)
[37, 38] to correct for the inﬂuence of heart rate. A senior
cardiologistevaluatedthePR,QRS,and QT intervalsvisually
on the ECG.
2.6. Statistical Analysis. Demographic and ECG results were
e n t e r e di n t oE p i D a t aa n de x p o r t e dt oS P S Sv e r s i o n1 2 . 0
and STATA version 8.0 for statistical analysis. Continuous
variables were summarized into means, and medians and
comparedusing the IndependentT-test. A P-value < .05was
considered statistically signiﬁcant.
3.Results
A total of 72 HIV-positive patients (41, 65% females) were
screened between January and June 2009; 12 (17%) were
excluded because they had other concurrent illnesses that
required treatment, 28 (39%) were excluded because they
had abnormal ECG tracings and 32 (44%) were enrolled,
16 in each arm. Patients in the two study arms were
comparable on majority of baseline characteristics (Table 1);
however, patients in the LPV/r arm had signiﬁcantly higher
hemoglobin levels with lower viral load.
There were no serious adverse events during the study
period. ECG parameters (heart rate, PR-interval, QRS-
complex and QTc) remained well within normal limits in
bothstudyarms (Table 2).The mean QRS-complexand QTc
interval after AL administration were higher in the LPV/r
arm compared to the ART na¨ ıve arm (87.4 versus 82.8,
P = .06 and 421 versus 404, P = .03, resp.) but the mean
PR-interval was signiﬁcantly higher in the ART na¨ ıve arm
(154 versus 169, P = .02) (Table 2). Mean (SD) change in
Table 3: shows the median QTc interval measurements in millisec-
onds over 72 hours period after AL dosing.
Time QTc (ms) median (IQR) P value
LPV/r arm ART na¨ ıve arm
Screening 415 (403–439) 395 (388–425) .14
12 hours 415 (404–439) 419 (403–427) .7
24 hours 424 (401–434) 406 (393–411) .02
48 hours 411 (396–432) 409 (401–419) .7
72 hours 424 (416–441) 408 (392–417) .004
QTc interval values from the pre-AL QTc interval values was
greater for the ART na¨ ıve arm compared to the LPV/r arm
(6.7 (15.4) versus −0.8 (13), P = .17). The QTc interval
measurements for participants in both study arms remained
within normal ranges over the 72 hours period (Table 3);
with none abovethe upperlimit ofnormal (450ms formales
and 470ms for females).
4.Discussion
LPV/r is a potent inhibitor of CYP3A4, therefore, coadmin-
istration with AL which is predominantly metabolized by
CYP3A4may potentially resultin enhanced pharmacological
andtoxicologicaleﬀects.Weaimedtoassess thecardiacsafety
of coadministration of a single dose (80/480mg) of AL in
HIV-infected patients taking LPV/r based ART and HIV
positive ART na¨ ıve patients. Since LPV/r is a potent CYP3A4
inhibitor, only a single dose of ALwas givenin orderto avoid
any unknown potential adverse eﬀects of the latter.
We found that HIV-positive patients taking LPV/r had a
higher QTc interval prior to administration of AL compared
to HIV-positive ART na¨ ıve patients, nevertheless, the diﬀer-
ence was not statistically signiﬁcant. It is possible that this
could have been a result of the eﬀects of LPV/r on the heart;
however, we cannot establish a causal relationship since we
did not have QTc measurements for these patients prior to
initiation of LPV/r. This however, raises concern especially
in view of the recent FDA alert over the eﬀects of LPV/r
on the heart. Indeed the label for LPV/r includes warnings
and precautions regarding QT/QTc interval and PR interval
prolongation [10].
Although the QTc interval for the LPV/r arm was
signiﬁcantly higher than that for the ART na¨ ıve arm at
72 hours, the diﬀerence could not be attributed to LPV/r
coadministration with AL because baseline QTc interval
w a sh i g h e ri nt h eL P V / ra r ma n db o t hs t u d ya r m sh a d
an increment in QTc interval values from baseline which
remained well within normal limits (Table 3). It is possible
thattheincrementintheQTcintervalscouldhavebeenmore
if patients had received the full six-dose regimen of AL. The
LPV/r label clearly states that LPV/r should be avoided in
patients using drugs that prolong the QT interval. Since we
do not know what levels and eﬀects of lumefantrine would
result if the full six-dose AL regimen is coadministered with
LPV/r, we suggest close clinical monitoring of HIV-positive
patientstakingLPV/rwithALconcomitantlyuntilmoredata
becomes available.4 Chemotherapy Research and Practice
This is one of the very few studies that have assessed the
cardiac safety of coadministration of AL and LPV/r in HIV
positivepatients.PreviousstudieshaveevaluatedsafetyofAL
inhealthyvolunteersandpatientswithmalaria. Bindschedler
and others found that the QTc interval remained unchanged
after a single dose of AL in healthy males [14]. The
diﬀerencein results may be explained by the diﬀerencein the
study populations. Bindschedler and others demonstrated
signiﬁcant exposure dependent increase in the QTc interval
in healthy males after halofantrine. It is possible that LPV/r
coadministered with a full six-dose regimen of AL may cause
increased concentrations of lumefantrine causing an expo-
sure dependent QTc interval prolongation. Previous data
showed no evidence of cardiotoxicity during AL treatment
in healthy volunteers [18]. However, these were conducted
in patients with malaria without coadministration of LPV/r.
It is possible that results may be diﬀerent with concomitant
treatment with the full six-dose AL regimen and LPV/r.
5.Conclusionand Recommendation
Our data suggests no evidence of cardiac conduction abnor-
malities after concomitanttreatment with LPV/r and a single
dose AL. There is need to assess the safety of the full six-dose
regimenofALinHIVpositivepatientsreceivingLPV/rbased
ART.
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